Home > Journals > Biology and research > European Cytokine Network > Full text
      Advanced search    Shopping cart    French version 
Latest books
All journals
Biology and research
European Cytokine Network
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
How can I publish?
Help for advertisers
Foreign rights
Book sales agents


Texte intégral de l'article
  Printable version

BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines

European Cytokine Network. Volume 9, Number 2, 181-6, June 1998, Articles originaux


Author(s) : R.F.M. Bevers, E.C. de Boer, K.H. Kurth, D.H.J. Schamhart.

Summary : Intravesical bacillus Calmette-Guérin (BCG) is a successful therapy for superficial bladder cancer. However, the working mechanism of BCG after intravesical instillation is not completely understood. A functional role of urothelial (tumor) cells in the initiation of the BCG-induced immune reaction should be considered. Here, the possibility of a causal relationship between BCG-induced interleukin-6 (IL-6) synthesis and BCG internalization by urothelial tumor cells was examined in a series of human transitional bladder cancer (TCC) cell lines with different degrees of differentiation. The results showed that the well differentiated TCC cell lines, RT4, SBC-2, and SBC-7, did not posses the capacity to internalize BCG, which was associated with an inability to upregulate IL-6 synthesis when stimulated with BCG. Moreover, these cell lines expressed a low level of constitutive IL-6 synthesis. In contrast, the poorly differentiated TCC cells, T-24, TCC-SUP and J-82, were able to internalize BCG. In T24 and J82, but not in TCC-SUP cells, BCG internalization appeared to result in an upregulation of IL-6 synthesis. Constitutive IL-6 synthesis of the high grade cell lines was found to be cell line-dependent: both TCC-SUP and J82 cells exhibited a high level of constitutive IL-6 synthesis, whereas T24 cells exhibited a low level. The possible relationship between BCG internalization and IL-6 upregulation was studied in detail with the T24 cell line, which exhibited a low constitutive and high BCG-inducible IL-6 synthesis, using anti-BCG anti-bodies ( BCG) and Cytochalasin B as internalization inhibitors. Upregulation of IL-6 synthesis was significantly inhibited by BCG or Cytochalasin B, indicating that internalization is a prerequisite for BCG-induced upregulation of IL-6 synthesis. In conclusion, upregulation of IL-6 production due to BCG internalization by poorly differentiated bladder carcinoma cells may be part of the mode of action of intravesical BCG therapy.

Keywords : phagocytosis, cytokines, Mycobacterium bovis, bladder neoplasms, cell lines.




Intravesical BCG therapy has been successfully used for the treatment of superficial bladder cancer [1, 2]. For BCG therapy to be effective, the development of an immune response seems to be important, although the exact mechanism remains to be established [3]. For the initiation of the immune reaction, several steps during the first interaction of BCG with the bladder wall have been suggested to be involved. These initial reactions may include BCG adherence and internalization, cytokine production and BCG antigen presentation by bladder (carcinoma) cells.

The immediate fate of BCG after intravesical instillation is not known. Several lines of evidence suggest internalization of BCG by urothelial cells in the initiation of the BCG-induced immune reaction and/or anti-tumor effect. Attachment and internalization of BCG by bladder tumor cells have been reported [4, 5]. Ingestion of mycobacteria both in vitro and in vivo by other non-professional phagocytic cells has also been reported [6]. The nature of the attachment as well as the number of bacteria attached to the bladder wall and/or urothelial cells are matters of controversy [7-11].

As a reaction to BCG therapy, urothelial cells are able to express several molecules such as MHC class II and ICAM-1 antigens on their cell wall [12, 13]. These molecules are fundamental to many immune functions including antigen presentation and cell-mediated cytotoxicity. BCG-antigen presentation to murine T-lymphocytes by urothelial cells has been reported [13]. In addition, intravesical BCG instillation is associated with an increased level of urinary cytokines [14-16]. The source of some of these cytokines has not been conclusively determined, but epithelial cells, including urothelial cells, do express the capacity to synthesize cytokines [17, 18]. Recently, accumulating data have shown that BCG is capable of upregulating cytokine synthesis such as IL-6 by tumor urothelial cells grown in vitro [19, 20]. In patients, IL-6 levels in urine following BCG instillation are reported to be related to the clinical BCG anti-tumor response [20].

In this study the hypothesis that BCG internalization depends on the degree of differentiation of TCC cells and is a prerequisite for upregulation of IL-6 production by bladder tumor cells was tested.


Cells and culture conditions

Stock cultures of a series of cell lines derived from human bladder carcinomas consisting of the well differentiated cell lines, RT-4 (grade 1), SBC-2 (grade 1), SBC-7 (grade 1) and the poorly differentiated cell lines, T24 (grade 3), TCC-SUP (grade 3) and J82 (grade 3) [21-23], were cultured as monolayers in standard Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 1% L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were grown at 37° C in a humidified 5% CO2 atmosphere at pH 7.2 until subconfluency. Cultures were routinely screened for mycoplasma.

For passage, cells were trypsinized with 0.05% trypsin and 0.02% EDTA in phosphate buffered saline (PBS). All tissue culture chemicals were obtained from Flow Laboratories (Irvine, Scotland). Tissue culture plastics were from Costar (Cambridge, Mass., USA).

BCG preparation

Freeze-dried BCG, Connaught strain (3.2 x 108 CFU per vial), was reconstituted in 10 ml prewarmed DMEM. To eliminate large clumps of bacteria, the suspension was centrifuged at 300 g for 3 min and the top 5 ml was used [5]. The concentration of CFU was set by measuring the absorbance at a wavelength of 440 nm, compared to a standard curve relating the CFU count to optical density.

Fluorescence activated cell sorter (FACS) analysis of BCG internalization by bladder cancer cell lines

Attachment and internalization of BCG were quantitated as described previously [11]. Briefly, cells (3 x 105/24-well) were cultured overnight, and BCG (Connaught) labelled with fluorescein isothiocyanate (FITC) was added. Cells were incubated with BCG-FITC for 4 hours, followed by washing, and harvesting with cell dissociation solution (CDS) obtained from Sigma (St Louis, MO, USA). This procedure resulted in cells containing both attached and internalized BCG-FITC. To exclusively stain the fraction of extracellular or attached BCG, cells were subsequently pre-incubated with polyclonal rabbit anti-BCG antibodies (alphaBCG) (1:100; Dakopatts, Denmark) followed by incubation with phycoerythrin (PE) conjugated goat anti-rabbit antibodies (1:25; Sigma, St Louis, MO, USA).

Cells (104) were measured with a fluorescence-activated cell sorter (FACScan, Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA), to determine the fraction of cells "stained" with FITC (Fl1+; intra- and extracellular BCG) and PE (Fl2+; extracellular BCG). The percentage of Fl1+/Fl2­ cells was taken as the percentage BCG-ingesting cells.

Inhibition studies of BCG phagocytosis

Inhibition of internalization of BCG was studied using alphaBCG (1:100-1:25) and rabbit polyclonal anti-FN antibodies (alphaFN) (1:100-1:25; Dako Corp., Santa Barbara, CA), added 30 min prior to the FACS internalization assay of BCG. To eliminate the effect of possible aspecific binding of the Fc portion of alphaFN to BCG, inhibition experiments were also performed with goat anti-human FN F(ab)2 fragments (1:100-1:25; Organon Teknika, West Chester, PA). For inhibition studies with Cytochalasin B (CytB;Sigma, St Louis, MO, USA), CytB at the indicated concentrations was added to the cells 1 hour before and during the incubation with BCG.

Determination and inhibition of constitutive and BCG-induced upregulation of IL-6 production

Cells (3 x 105 cells) were continuously incubated with BCG at the indicated concentrations. At the indicated time intervals, medium was collected for cytokine determinations. IL-6 was quantified with a human specific, oligoclonal ELISA obtained from Medgenix (Fleurus, Belgium) [24]. Conditions for inhibition of IL-6 production by alphaBCG, alphaFN and CytB were similar as those described for the inhibitory studies of BCG internalization.

Statistical analysis

All experiments were performed at least twice. FACS analysis measurements represent the mean of duplicate cultures, SD was less than 10%. All experiments concerning IL-6 measurements were performed in triplicate. For comparison between groups the Mann-Whitney test or Student's t test for independent samples were used (SPSS 6.1 for Microsoft Windows software).


Internalization of BCG

The kinetics of BCG internalization in T24 cells have been reported in a previous study [11]. The percentage of cells internalizing BCG appeared to be proportionally related to the time of incubation. As presented in Figure 1, the capacity for BCG internalization in a series of human bladder cancer cell lines appeared to be cell-line dependent. The maximum number of cells internalizing BCG during a period of 24 hours varied from 0-2% for the well differentiated cell lines (RT-4, SBC-2 and SBC-7), to 34-68% for the poorly differentiated cell lines (T-24, TCC-SUP and J-82). These data suggest a relationship between the capacity to internalize BCG and the differentiation grade of TCC cells. Only poorly differentiated tumor cell lines internalized BCG.

BCG-induced and constitutive IL-6 synthesis

To study BCG internalization as a necessary initial step of BCG-induced upregulation of IL-6, initially both the constitutive and BCG-induced upregulation of IL-6 were determined in a series of well and poorly differentiated cell lines. As illustrated in Figure 2 constitutive and BCG-mediated upregulation of IL-6 appeared to be cell line-dependent. Determined after a 7 hours incubation period, the well differentiated, non-phagocytic cell lines (SBC-2 and SBC-7) exhibited low (0.4 to 0.5 ng/3 x 105 cells) constitutive IL-6 synthesis, which appeared not to be upregulated in the presence of BCG (0.5 ng/3 x 105 cells). Of the poorly differentiated, BCG internalizing cell lines, the constitutive IL-6 synthesis was found to be high for TCC-SUP (1.1 ± 0.1 ng/3 x 105 cells) and J82 (1.7 ± 0.4 ng/3 x 105 cells) cells, but low (0.1 ± 0.0 ng/3 x 105 cells) for T24 cells. Stimulation with BCG did not significantly (p = 0.095) upregulate IL-6 synthesis in TCC-SUP cells. In contrast, both the J82 and T24 exhibited a significant (p < 0.005) upregulation of IL-6 production when stimulated with BCG. This BCG-induced upregulation was most pronounced in T24 cells, resulting in an IL-6 production of 2.6 ± 0.1 ng/ml compared to the constitutive synthesis of 0.1 ± 0.0 ng per 3 x 105 cells over a period of 7 hours. This upregulation of IL-6 production was BCG concentration-and time-dependent (Figure 3). So, the poorly differentiated TCC cell lines showed, in addition to the capacity to internalize BCG, either a high constitutive (TCC-SUP and J82) and/or a high BCG-inducible production of IL-6 (T24 and J82).

Relation between BCG phagocytosis and IL-6 production

The results outlined above suggest the possibility of a causal relationship between BCG internalization and IL-6 upregulation, which is especially illustrated in T24 cells. In a subsequent series of experiments, the possibility of BCG internalization as a prerequisite to BCG-induced IL-6 production was studied in detail. These experiments were performed with T24 cells, since the characteristics of this cell line, namely the low constitutive IL-6 synthesis associated with a high degree of BCG-induced upregulation of IL-6 synthesis, seemed to be well suited for this purpose.

Incubation with BCG, pretreated with alphaBCG, decreased the percentage of T24 cells associated with BCG to 34% (1:100 alphaBCG) and 12% (1: 25 alphaBCG) compared to 38% in the absence of alphaBCG (data not shown). As illustrated in Figure 4, under similar conditions a significant (p = 0.028) inhibition of BCG-induced upregulation of IL-6 synthesis occurred in the presence of alphaBCG at a concentration of 1:25.

A condition previously found to reduce the internalization of BCG by T24 cells specifically [11], namely incubation with CytB, was subsequently tested for its ability to prevent IL-6 upregulation. Under conditions where CytB reduced BCG internalization by T24 cells to 46%, Cyt B inhibited BCG-induced IL-6 production, which was significantly stronger than the inhibition of the constitutive IL-6 synthesis (Table 1).

Kuroda et al. [4] suggest that BCG internalization is associated with fibronectin and can be inhibited by alphaFN. Using identical antibodies the effect of alphaFN on BCG-induced upregulation of IL-6 synthesis was studied. The results, presented in Figure 4, show that addition of alphaFN to T24 cells and subsequent incubation with BCG did not inhibit BCG-induced IL-6 upregulation (2.3 ± 0.1 versus 2.2 ± 0.2 ng/ml per 3 x 105 cells in the absence of alphaFN; p = 0.272). Since this observation contradicted our expectations, the effect of alphaFN on BCG internalization was determined. The results indicated that alphaFN, added at concentrations ranging from 1:100 to 1:25, did not inhibit BCG internalization (data not shown). So, these results seemed to be in agreement with the absence of an effect of alphaFN on the induction of IL-6 synthesis by BCG.

Overall, the data suggest that in T24 cells, internalization of BCG is a prerequisite for BCG-induced IL-6 production.


Various cytokines can be detected in the urine of patients treated with BCG intravesically [14, 15, 25]. Internalization of BCG by urothelial cells in vivo has been reported [5]. This implies that the present study concerning BCG internalization and cytokine production of urothelial cells in vitro may be of clinical relevance.

In this study, the phagocytic capacity and high levels of IL-6 production, either constitutive or BCG-induced or both, seemed to be restricted to cell lines with a poor degree of differentiation (T24, TCC-SUP and J82, grade 3). Tumor grade dependency has already been reported with regard to adherence of BCG to bladder tumor cell lines [26], and (BCG-induced) IL-6 production by bladder tumor cell lines [20]. In addition, the present results suggested a relationship between BCG-internalization and IL-6 production. Experiments with Cytochalasin B, a molecule which specifically blocks phagocytosis [11], showed internalization of BCG to be a prerequisite for the BCG-induced IL-6 production in T24 tumor cells. Accepting the hypothesis that BCG internalization and (BCG-induced) cytokine production of (tumor) urothelial cells may play a central role in the mechanism of action of BCG, these findings are in accordance with clinical observations that high grade tumors show a better response to BCG treatment than lower grade tumors [27].

The observed capacity of high grade TCC tumor cells to produce IL-6, either constitutively and/or during stimulation with BCG, may reflect the clinical situation. Following instillations with BCG, various cytokines can be detected in the urine of patients [14, 15, 25]. These observations suggest that, during intravesical BCG instillation, urothelial (tumor) cells may be a significant source of urinary cytokines, additional to the major cellular sources, such as macrophages and lymphocytes infiltrating the bladder wall. It has been speculated that a BCG-induced upregulation of cytokines in urothelial (tumor) cells of the bladder could be of functional significance in vivo, initiating and/or modulating the BCG-induced immune response [24, 25, 28]. It should be noted that upregulation of the cytokine synthesis of urothelial tumor cells by microorganisms seems to be a characteristic most extensively expressed in the presence of BCG. It has been shown that the upregulation of IL-6 and TNF-alpha synthesis in T24 cells by BCG is at least 10 times higher compared to the upregulation by E. Coli or S. faecalis [19].

As indicated for T24 cells, upregulation of IL-6 production appeared to be related to the dose of BCG. An optimal dose in vitro was not established with the concentration range used. In patients however, the dose may be limited by the adverse side effects of BCG [29].

In order to inhibit BCG internalization by T24 cells, we used, in addition to Cytochalasin B, polyclonal alphaBCG and alphaFN as described by Kuroda et al [4]. In accordance with these investigators, we observed a decreased internalization due to alphaBCG, suggesting a specific interaction between BCG and the T24 cellular membrane. This condition also reduced the BCG-induced IL-6 upregulation by T24, which further consolidated the findings with Cytochalasin B. In contrast to Kuroda et al. we could not detect an inhibiting effect of alphaFN on BCG phagocytosis. This discrepancy cannot be explained by the use of different sources of antibodies. Furthermore, differences in BCG strains do not seem likely since thusfar all strains have shown to be comparable with regard to clinical efficacy against superficial bladder tumors. Absence of an inhibiting effect of alphaFN for BCG phagocytosis by bladder carcinoma cell lines has been reported by other investigators too [26, 30]. These observations do not favour the previously suggested (opsonizing) role of FN in BCG internalization by bladder tumor cells [4]. However, there may be differences between the proposed role of FN in mediating BCG binding to the injured bladder wall, initiation of an immune response and the associated antitumor activity in a mouse bladder tumor model [10] and the possible role of FN in the internalization of BCG in vitro systems.

In this study, alphaBCG inhibited in vitro internalization of BCG in T24 cells, and IL-6 production. Anti-BCG antibodies (IgG and IgA) have been shown to be present in serum and urine of patients following BCG instillations [9] up to 12 months after BCG therapy, possibly interfering with the effectiveness of subsequent BCG instillations. Whether the level of anti-BCG antibodies in patients correlates with the anti-tumor effect or not, and what the implications are for the efficacy of (maintenance) instillations with BCG, remains to be established in further studies.


A high constitutive IL-6 production or IL-6 upregulation, initiated by BCG internalization seems to be related to the degree of differentiation of the bladder cancer cell lines. These observations suggest that constitutive IL-6 production and/or BCG-mediated (after internalization) upregulation of IL-6 production by poorly differentiated bladder carcinoma cells may be part of the mode of action of intravesical BCG therapy. The role of this phenomenon in vivo, however, remains to be established.


This study was supported by a grant from the Urological Research Foundation Amsterdam (BUWO), The Netherlands and by Connaught Laboratories Ltd., North York, Ontario, Canada.


1. Herr H W, Pinsky C M, Whitmore W F Jr, Sogani P C, Oettgen H F, Melamed M R. 1986. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J. Urol. 135: 265.

2. Lamm D L, Blumenstein B A, Crawford E D, Montie J E, Scardoni P, Grossman H B, Stanisic T H, Smith Jr J A, Sullivan J, Sarosdy M F, Crissman J D, Coltman C A. 1991. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325: 1205.

3. Ratliff T L. 1989. Mechanism of action of intravesical BCG for bladder cancer. (Review) Prog. Clin. Biol. Res. 310: 107.

4. Kuroda K, Brown E J, Telle W B, Russell D G, Ratliff T L. 1993. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J. Clin. Invest. 91: 69.

5. Becich M J, Carroll S, Ratliff T L. 1991. Internalization of bacille Calmette-Guérin by bladder tumor cells. J. Urol. 145: 1316.

6. Band A H, Chitamber S D, Bhattacharya A, Talwar G P. 1986. Mechanism of phagocytosis of mycobacteria by Schwann cells and their comparison with macrophages. Int. J. Lepr. other Mycobact. Dis. 54: 294.

7. Kavoussi L R, Brown E J, Ritchey J K, Ratliff T L. 1990. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an anti-tumor response. J. Clin. Invest. 85: 62.

8. Teppema J S, de Boer E C, Steerenberg P A, van der Meijden A P. 1992. Morphological aspects of the interaction of bacillus Calmette-Guerin (BCG) with urothelial cells in vivo and in vitro: relevance for antitumor activity? Urol. Res. 20: 219.

9. Van der Sloot E, Kuster S, Böhle A, Braun J, Wood W G. 1992. Towards an understanding of the mode of action of bacillus Calmette-Guérin therapy in bladder cancer treatment, especially with regard to the role of fibronectin. Eur. J. Clin. Chem. Clin. Biochem. 30: 503.

10. Ratliff T L, Palmer J O, McGarr J A, Brown E J. 1987. Intravesical BCG therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of BCG. Cancer Res. 47: 1762.

11. De Boer E C, Bevers R F, Kurth K H, Schamhart D H. 1996. Double fluorescent flow cytometric quantification of bacterial internalization and binding by epithelial cells. Cytometry 25: 381.

12. Jackson A M, Alexandroff A B, McIntyre M, Esuvara-
nathan K, James K, Chisholm G D. 1994. Induction of ICAM-1 expression on bladder tumours by BCG immunotherapy. J. Clin. Pathol. 47: 309.

13. Lattime E C, Gomella L G, McCue P A. 1992. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T cells. Cancer Res. 52: 4286.

14. Böhle A, Nowc C H, Ulmer A J, Musehold J, Hofstetter A G, Flad H D. 1992. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol. 144: 59.

15. De Boer E C, de Jong W H, Steerenberg P A, Aarden L A, Tetteroo E, de Groot E R, van der Meijden P, Vegt P D, Debruyne F M, Ruitenberg E J. 1992. Induction of urinary IL-1, IL-2, IL-6, and TNF during intravesical immunotherapy with BCG in superficial bladder cancer. Cancer Immunol. Immunother. 34: 306.

16. De Reijke T M, de Boer E C, Kurth K H, Schamhart D H. 1996. Urinary cytokines during intravesical BCG therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol. 155: 477.

17. Thompson A B, Robbins R A, Romberger D J, Sisson J H, Spurzem J R, Teschler H, Rennard S I. 1995. Immunological functions of the pulmonary epithelium. (Review) Eur. Resp. J. 8: 127.

18. Hedges S, Agace W, Svensson M, Sjögren A C, Ceska M, Svanborg C. 1994. Uroepithelial cells are part of a mucosal cytokine network. Infect. Immun. 62: 2315.

19. De Reijke T M, Vos P C, de Boer E C, Bevers R F, de Muinck Keizer W H, Kurth K H, Schamhart D H. 1993. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol. Res. 21: 349.

20. Esuvaranathan K, Alexandroff A B, McIntyre M, Jackson A M, Prescott S, Chisholm G D, James K. 1995. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J. Urol. 154: 572.

21. Hansson Y, Vargas-Cortes M, Paulie S, Perlmann P. 1988. MHC nonrestricted cytotoxic T cell clones with selective specificity from patients with transitional cell carcinoma of the urinary bladder. Cancer Immunol. Immunother. 27: 205.

22. Wang M H, Flad H D, Böhle A, Chen Y Q, Ulmer A J. 1991. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol. Lett. 27: 191.

23. Johansson S L, Unsgaard B, O'Toole C M. 1994. Cell lines from urinary bladder tumors. In: Hay R J, Park J G, Gazdar A, Eds. Atlas of human tumor cell lines, New York: Academic Press Inc., 341.

24. Schamhart D H, Kurth K H, de Reijke T M, Vleeming R. 1992. BCG treatment and the importance of an inflammatory response. Urol. Res. 20: 199.

25. De Boer E C, Somogyi L, de Ruiter G J, de Reijke T M, Kurth K H, Schamhart D H. 1997. Role of IL-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol. Res. 25: 31.

26. Schneider B, Thanhauser A, Jocham D, Loppnow H, Vollmer E, Galle J, Flad H D, Ulmer A J, Böhle A. 1994. Specific binding of bacillus Calmette-Guerin to urothelial tumor cells in vitro. World J. Urol. 12: 337.

27. Melekos M D, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G, Dauaher H. 1993. Intravesical BCG immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J. Urol. 149: 744.

28. Jackson A M, James K. 1994. Understanding the most successful immunotherapy for cancer. The immunologist 2/6: 208.

29. Kreider J W, Bartlett G L, Purnell D M. 1980. Immunotherapeutic effectiveness of BCG inactivated by various modalities. Cancer 46: 480.

30. Vögeli T A, Geisler D, Schroten H, Ackermann R. 1993. Evidence for fibronectin-independent binding of BCG Pasteur in cell culture systems of urothelial cancer. J. Urol. 149: 337a (abstract).


About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]